Addition of the immunotherapy drug pembrolizumab to standard of care for patients with advanced soft tissue sarcoma of the limb significantly improved disease-free survival, according to the results ...

A new study in Cell Reports Medicine from researchers at The University of Texas MD Anderson Cancer Center identified key ...

BioInvent International (STO:BINV)24% confirmed ORR (including complete response) in heavily pretreated patients (n=25) with advanced ovarian cancer who received BI-1808 and KEYTRUDA - multiplying by ...

Injectable pembrolizumab can treat several types of cancer and can be administered in under two minutes ...

A study published April 10 in The Lancet reports that the anti-PD-1 immunotherapy pembrolizumab (brand name Keytruda) significantly improved overall survival in adults with platinum-resistant ovarian ...

Clinical and Molecular Characteristics of High-Risk, Recurrent, or Metastatic Endometrial Cancer That Is Human Epidermal Growth Factor Receptor 2–Low In this multicenter phase I trial, we enrolled ...

The FDA approved pembrolizumab (Keytruda) plus paclitaxel for recurrent ovarian cancers that express PD-L1, the agency announced on Tuesday. Approval stipulates use of the combination, with or without ...

After decades of minimal progress in the treatment of human papillomavirus (HPV)-negative head and neck squamous cell carcinoma (HNSCC), the recent publication of KEYNOTE-689 has led many to conclude ...

Nivolumab (Opdivo) plus ipilimumab (Yervoy) combined with chemotherapy for the first-line treatment of non-small cell lung cancer (NSCLC) did not improve overall survival (OS) and led to more adverse ...

Every participant in a new bowel cancer immunotherapy trial remained cancer-free nearly three years after receiving pembrolizumab before surgery.